Although response rates were higher in patients with EGFR mutant tumours, the use of erlotinib in molecularly unselected NSCLC patients after failure of one or two lines of chemotherapy demonstrated modest survival and quality of life benefit compared to placebo in all patients [17, 18]. This evidence concerns the gene EGFR and neoplasm.